Bioimpacts. 2016;6(1): 49-67. doi: 10.15171/bi.2016.07
PMID: 27340624        PMCID: PMC4916551


Advanced drug delivery and targeting technologies for the ocular diseases

Cited by CrossRef: 30

1- Cañadas-Enrich C, Abrego G, Alvarado H, Calpena-Campmany A, Boix-Montañes A. Pranoprofen quantification in ex vivo corneal and scleral permeation samples: Analytical validation. Journal of Pharmaceutical and Biomedical Analysis. 2018;160:109 [Crossref]
2- Kopp F, Eickner T, Polei S, Falke K, Witt M, Grabow N, Stachs O, Guthoff R, Lindner T. Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model. Sci Rep. 2017;7(1) [Crossref]
3- Pietrucha-Dutczak M, Amadio M, Govoni S, Lewin-Kowalik J, Smedowski A. The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration. Front Neurosci. 2018;12 [Crossref]
4- Balguri S, Adelli G, Janga K, Bhagav P, Majumdar S. Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol. International Journal of Pharmaceutics. 2017;529(1-2):32 [Crossref]
5- Wong C, Czarny B, Metselaar J, Ho C, Ng S, Barathi A, Storm G, Wong T. Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis. Sci Rep. 2018;8(1) [Crossref]
6- Sharif N. Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision. Neural Regen Res. 2018;13(7):1145 [Crossref]
7- Zangabad P, Mirkiani S, Shahsavari S, Masoudi B, Masroor M, Hamed H, Jafari Z, Taghipour Y, Hashemi H, Karimi M, Hamblin M. Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications. 2018;7(1):95 [Crossref]
8- Barar J, Rafi M, Pourseif M, Omidi Y. Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016;6(4):225 [Crossref]
9- Sherwin J, Ratnarajan G, Elahi B, Bilkiewicz-Pawelec A, Salmon J. Effect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial. Clin Experiment Ophthalmol. 2018;46(8):888 [Crossref]
10- Agrahari V, Agrahari V, Mandal A, Pal D, Mitra A. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. Expert Opinion on Drug Delivery. 2017;14(10):1145 [Crossref]
11- Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomedicine & Pharmacotherapy. 2018;107:1564 [Crossref]
12- Awwad S, Al-Shohani A, Khaw P, Brocchini S. Comparative Study of In Situ Loaded Antibody and PEG-Fab NIPAAM Gels. Macromol Biosci. 2018;18(2):1700255 [Crossref]
13- Habot-Wilner Z, Noronha G, Wykoff C. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019; [Crossref]
14- Safary A, Akbarzadeh Khiavi M, Mousavi R, Barar J, Rafi M. Enzyme replacement therapies: what is the best option?. Bioimpacts. 2018;8(3):153 [Crossref]
15- Bisht R, Jaiswal J, Rupenthal I. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye. Medical Hypotheses. 2017;103:5 [Crossref]
16- Irimia T, Ghica M, Popa L, Anuţa V, Arsene A, Dinu-Pîrvu C. Strategies for Improving Ocular Drug Bioavailability and Corneal Wound Healing with Chitosan-Based Delivery Systems. Polymers. 2018;10(11):1221 [Crossref]
17- Jin S, Hwang S. Ocular delivery systems for the administration of antibody therapeutics. Journal of Pharmaceutical Investigation. 2017;47(5):373 [Crossref]
18- Garg V, Suri R, Jain G, Kohli K. Proglycosomes: A novel nano-vesicle for ocular delivery of tacrolimus. Colloids and Surfaces B: Biointerfaces. 2017;157:40 [Crossref]
19- Chen C, Liu K, Xu Y, Zhang P, Suo Y, Lu Y, Zhang W, Su L, Gu Q, Wang H, Gu J, Li Z, Xu X. Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution. Biomaterials. 2017;112:218 [Crossref]
20- Maharjan P, Cho K, Maharjan A, Shin M, Moon C, Min K. Pharmaceutical challenges and perspectives in developing ophthalmic drug formulations. J Pharm Investig. 2019;49(2):215 [Crossref]
21- Kubo Y, Akanuma S, Hosoya K. Recent advances in drug and nutrient transport across the blood-retinal barrier. Expert Opinion on Drug Metabolism & Toxicology. 2018;14(5):513 [Crossref]
22- Awwad S, Mohamed Ahmed A, Sharma G, Heng J, Khaw P, Brocchini S, Lockwood A. Principles of pharmacology in the eye. British Journal of Pharmacology. 2017;174(23):4205 [Crossref]
23- Emami A, Tepper J, Short B, Yaksh T, Bendele A, Ramani T, Cisternas A, Chang J, Mellon R. Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular. Int J Toxicol. 2018;37(1):4 [Crossref]
24- Mandal A, Pal D, Agrahari V, Trinh H, Joseph M, Mitra A. Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. Advanced Drug Delivery Reviews. 2018;126:67 [Crossref]

BioImpacts, as a peer-reviewed international journal, publishes all types of papers on bench-to-bedside translational aspects of pharmaceutical and biomedical sciences. As a "Publish Free" and "Access Free" journal, BioImpacts follows a constructive peer-review process with free editing service to benefit the scientific community worldwide.